Clinical trials · New York, NY
Metastatic Pancreatic Ductal Adenocarcinoma clinical trials in New York
We’re tracking 42 recruiting metastatic pancreatic ductal adenocarcinoma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
New York, New YorkAges 18 years+ - NCT05851924RecruitingPhase 2
Nalirifox plus radiation for nonmetastatic pancreatic cancer
This trial studies Nalirifox (chemotherapy) given together with radiation therapy for pancreatic ductal adenocarcinoma that has not spread to distant organs. It may help shrink the cancer and improve local control, especially when surgery is not an option right now.
New York, New YorkAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
New York, New YorkAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
New York, New YorkAges 18 years+ - NCT07049055RecruitingPhase 1/Phase 2
EDV nanocell therapy with chemo for advanced pancreatic cancer
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
New York, New YorkAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
New York, New YorkAges 18 years+ - NCT05241249RecruitingPhase 2
Bethanechol plus chemotherapy for pancreatic cancer
This trial tests whether adding bethanechol to standard chemotherapy (gemcitabine and nab-paclitaxel) can work better for people with pancreatic ductal adenocarcinoma. You may be considered if your cancer is not spread and you can safely take the medicines and follow study visits.
New York, New YorkAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
New York, New YorkAges 18 years+ - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
New York, New YorkAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
New York, New YorkAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
New York, New YorkAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
New York, New YorkAges 18 years+ - NCT07217717RecruitingPhase 3
New PET scan for pancreatic cancer staging
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
New York, New YorkAges 18 years+ - NCT06005493RecruitingPhase 1/Phase 2
Study of AZD5863 for advanced stomach, esophagus, or pancreatic cancer
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
New York, New YorkAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
New York, New YorkAges 18 years+ - NCT07163273RecruitingPhase 2
Alternating chemotherapy for first-line metastatic pancreatic cancer
This study tests a monthly rotation of two chemotherapy combinations (NALIRIFOX and GnP) as the first treatment for metastatic pancreatic cancer. The goal is to see if alternating the drugs helps control the cancer while reducing side effects.
New York, New YorkAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT06922591RecruitingPhase 1/Phase 2
TNG462 for pancreatic and lung cancer with MTAP loss
This trial tests a new drug called TNG462, alone or combined with other drugs, for people with advanced pancreatic or non-small cell lung cancer whose tumors have a specific genetic change (loss of MTAP and a RAS mutation). It aims to see if TNG462 is safe and works better than current treatments.
New York, New YorkAges 18 years+ - NCT06989437RecruitingPhase 2/Phase 3
Study of Ponsegromab for Pancreatic Cancer with Weight Loss
This study tests an experimental drug called ponsegromab for people with advanced pancreatic cancer who experience severe weight loss and fatigue. It aims to see if the drug can help improve weight and energy levels while you continue standard chemotherapy.
New York, New YorkAges 18 years+ - NCT07644559RecruitingPhase 2
VS-7375 for KRAS G12D pancreatic cancer
This study tests a new drug called VS-7375, combined with cetuximab, for pancreatic cancer patients whose tumors have a specific genetic mutation called KRAS G12D. The goal is to see if this combination can shrink tumors and help patients live longer.
New York, New YorkAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
New York, New YorkAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
New York, New YorkAges 18 years+ - NCT07252232RecruitingPhase 3
A pill to prevent pancreatic cancer recurrence after surgery
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
New York, New YorkAges 18 years+
Hear when a new Metastatic Pancreatic Ductal Adenocarcinoma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Pancreatic Ductal Adenocarcinoma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic pancreatic ductal adenocarcinoma studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- NYU Langone Health · 6 studies
- Columbia University Irving Medical Center · 5 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- NYU Langone Health Perlmutter Cancer Center · 3 studies
- Research Site · 3 studies
- Rutgers Cancer Institute of New Jersey · 2 studies
- Atlantic Health System
What taking part in a metastatic pancreatic ductal adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic pancreatic ductal adenocarcinoma studies in New York.
Common questions
- Are there metastatic pancreatic ductal adenocarcinoma clinical trials near New York?
- Yes. We're currently tracking 42 recruiting metastatic pancreatic ductal adenocarcinoma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic pancreatic ductal adenocarcinoma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic pancreatic ductal adenocarcinoma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.